VIR Stock Price | Vir Biotechnology Inc P/E, Revenue, EPS, & Forecasts

Vir Biotechnology Inc • VIR

VIR current price

$7.39-27.69%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

+1.79%

+0.41%

+1.23%

-16.69%

-27.69%

MAX

-47.29%

About Vir Biotechnology Inc

Ticker

VIR

Trading on

NASDAQ

ISIN

US92764N1028

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Headquarters

1800 Owens Street, San Francisco, CA, United States, 94158

Employees

587

Website

vir.bio

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Metrics

BasicAdvanced

Market cap

$1.02B

P/E ratio

EPS

-$3.93

Dividend Yield

0.00%

Beta

0.46

Forward P/E ratio

4.36

EBIDTA

$-534M

Ex dividend date

Price & volume

Market cap

$1.02B

Average daily volume

1.5M

90-day return

1.23%

30-day return

0.41%

7-day return

1.79%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

4.36

PEG ratio

Trailing P/E

Price to sales

12.93

Price to book

0.82

Earnings

EPS

-$3.93

EPS estimate (current quarter)

-$1.05

EPS estimate (next quarter)

-$0.89

EBITDA

$-534M

Revenues (TTM)

$78.6M

Revenues per share (TTM)

$0.58

Technicals

Beta

0.46

52-week High

$13.09

52-week Low

$6.56

50-day moving average

$8.01

200-day moving average

$8.87

Short ratio

4.15

Short %

7.26%

Management effectiveness

ROE (TTM)

36.58%

ROA (TTM)

19.41%

Profit margin

0.00%

Gross profit margin

$1.03B

Operating margin

9,184.54%

Growth

Quarterly earnings growth (YoY)

58.50%

Quarterly revenue growth (YoY)

9.80%

Share stats

Outstanding Shares

138M

Float

92.5M

Insiders %

11.90%

Institutions %

74.37%

Analyst Insights & forecasts

67% Buy

33% Hold

0% Sell

Based on information from 9 analysts.

Average price target

$29.50

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.86

-$1.01

14.85%

Q4 • 23Beat

-$0.48

-$1.05

54.29%

Q1 • 24Beat

-$1.02

-$0.90

13.33%

Q2 • 24Beat

-$1.56

-$1.05

48.57%

Q3 • 24Beat

-$0.89

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$3.1M

$-138M

4,500.10%

Q2 • 24

$2.4M

$-214M

8,979.71%

Q3 • 24

22.60%

54.44%

99.54%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$1.67B

$236M

14.13%

Q2 • 24

$1.5B

$258M

17.19%

Q3 • 24

10.25%

9.22%

21.70%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-77.8M

$212M

$2.9M

$-78.5M

Q2 • 24

$-171M

$119M

$0M

$-174M

Q3 • 24

120.28%

43.95%

98.95%

121.41%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Greed

+1.5

0.60

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Vir Biotechnology Inc share?

Vir Biotechnology Inc shares are currently traded for $7.39 per share.

How many shares does Vir Biotechnology Inc have?

Vir Biotechnology Inc currently has 138M shares.

Does Vir Biotechnology Inc pay dividends?

No, Vir Biotechnology Inc doesn't pay dividends.

What is Vir Biotechnology Inc 52 week high?

Vir Biotechnology Inc 52 week high is $13.09.

What is Vir Biotechnology Inc 52 week low?

Vir Biotechnology Inc 52 week low is $6.56.

What is the 200-day moving average of Vir Biotechnology Inc?

Vir Biotechnology Inc 200-day moving average is $8.87.

Who is Vir Biotechnology Inc CEO?

The CEO of Vir Biotechnology Inc is Dr. Marianne De Backer M.B.A., M.Sc., Ph.D..

How many employees Vir Biotechnology Inc has?

Vir Biotechnology Inc has 587 employees.

What is the market cap of Vir Biotechnology Inc?

The market cap of Vir Biotechnology Inc is $1.02B.

What is the P/E of Vir Biotechnology Inc?

The current P/E of Vir Biotechnology Inc is null.

What is the EPS of Vir Biotechnology Inc?

The EPS of Vir Biotechnology Inc is -$3.93.

What is the PEG Ratio of Vir Biotechnology Inc?

The PEG Ration of Vir Biotechnology Inc is null.

What do analysts say about Vir Biotechnology Inc?

According to the analysts Vir Biotechnology Inc is considered a buy.

Vir Biotechnology Inc news

thumbs_up_down

•Neutral

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days. About.

Business Wire•18 Dec 2024, 14:30

thumb_up_alt

•Positive

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.

Seeking Alpha•13 Dec 2024, 17:57

thumbs_up_down

•Neutral

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AAS.

Business Wire•12 Dec 2024, 21:05